Elly Gerald Stoica

Array ( [id] => 13551855 [patent_doc_number] => 20180327475 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-15 [patent_title] => NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS [patent_app_type] => utility [patent_app_number] => 16/044266 [patent_app_country] => US [patent_app_date] => 2018-07-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 43232 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 146 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16044266 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13549081 [patent_doc_number] => 20180326088 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-15 [patent_title] => COMPOSITIONS AND METHODS FOR TREATING CANCER [patent_app_type] => utility [patent_app_number] => 16/042789 [patent_app_country] => US [patent_app_date] => 2018-07-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38523 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16042789 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15254229 [patent_doc_number] => 20190375848 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-12 [patent_title] => USE OF ANTI-TUMOUR EFFECTS OF A 'HUMAN & MOUSE CROSS-REACTIVE' ANTI-ADAM17 ANTIBODY IN TREATING PANCREATIC CANCER [patent_app_type] => utility [patent_app_number] => 16/033654 [patent_app_country] => US [patent_app_date] => 2018-07-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6951 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16033654 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16189371 [patent_doc_number] => 20200230220 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-23 [patent_title] => NEOANTIGEN VACCINE COMPOSITION FOR TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 16/626750 [patent_app_country] => US [patent_app_date] => 2018-07-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12089 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16626750 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17275839 [patent_doc_number] => 20210382037 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-09 [patent_title] => IDENTIFICATION AND USE OF CYTOTOXIC T LYMPHOCYTE (CTL) ANTIGEN-SPECIFIC TARGET CELL KILLING ENHANCER AGENTS [patent_app_type] => utility [patent_app_number] => 16/629930 [patent_app_country] => US [patent_app_date] => 2018-07-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27641 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -36 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16629930 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16156633 [patent_doc_number] => 20200216549 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-09 [patent_title] => METHODS TO IMPROVE ANTI-ANGIOGENIC THERAPY AND IMMUNOTHERAPY [patent_app_type] => utility [patent_app_number] => 16/628941 [patent_app_country] => US [patent_app_date] => 2018-07-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31356 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16628941 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15931169 [patent_doc_number] => 20200157218 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-21 [patent_title] => BISPECIFIC ANTIBODIES TO ROR1 AND CD3 [patent_app_type] => utility [patent_app_number] => 16/628404 [patent_app_country] => US [patent_app_date] => 2018-07-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21142 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16628404 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16341651 [patent_doc_number] => 20200306301 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-01 [patent_title] => Polynucleotides Encoding Immunostimulatory Fusion Molecules and Uses Thereof [patent_app_type] => utility [patent_app_number] => 16/628363 [patent_app_country] => US [patent_app_date] => 2018-07-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 73561 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 68 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16628363 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15963191 [patent_doc_number] => 20200165347 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-28 [patent_title] => METHOD OF TREATMENT USING IL-13R ANTIBODY [patent_app_type] => utility [patent_app_number] => 16/625902 [patent_app_country] => US [patent_app_date] => 2018-06-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12505 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16625902 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17044942 [patent_doc_number] => 11098110 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-08-24 [patent_title] => Methods for treating ocular diseases with brolucizumab [patent_app_type] => utility [patent_app_number] => 16/018244 [patent_app_country] => US [patent_app_date] => 2018-06-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 7396 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 94 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16018244 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18369132 [patent_doc_number] => 11649286 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-05-16 [patent_title] => Tri-specific antibodies [patent_app_type] => utility [patent_app_number] => 16/615117 [patent_app_country] => US [patent_app_date] => 2018-06-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 10932 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 135 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16615117 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15927771 [patent_doc_number] => 20200155519 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-21 [patent_title] => METHODS FOR TREATING CANCER WITH COMPOSITIONS COMPRISING AMLEXANOX AND IMMUNE MODULATORS [patent_app_type] => utility [patent_app_number] => 16/623696 [patent_app_country] => US [patent_app_date] => 2018-06-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26195 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16623696 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16215151 [patent_doc_number] => 10730949 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-08-04 [patent_title] => Method of treating PVNS with anti-CSF1R antibodies [patent_app_type] => utility [patent_app_number] => 16/015371 [patent_app_country] => US [patent_app_date] => 2018-06-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 37618 [patent_no_of_claims] => 35 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 172 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16015371 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13476461 [patent_doc_number] => 20180289773 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-10-11 [patent_title] => COMPOSITIONS FOR TREATING LUNG INFECTIONS BY AIRWAY ADMINISTRATION [patent_app_type] => utility [patent_app_number] => 16/014818 [patent_app_country] => US [patent_app_date] => 2018-06-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12542 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16014818 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13826565 [patent_doc_number] => 20190016767 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-17 [patent_title] => MULTIMODAL TRAIL MOLECULES AND USES IN CELLULAR THERAPIES [patent_app_type] => utility [patent_app_number] => 16/014841 [patent_app_country] => US [patent_app_date] => 2018-06-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 42756 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16014841 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16791658 [patent_doc_number] => 20210121475 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-29 [patent_title] => IMIPRAMINE COMPOSITIONS AND METHODS OF TREATING CANCER [patent_app_type] => utility [patent_app_number] => 16/617414 [patent_app_country] => US [patent_app_date] => 2018-06-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10278 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -72 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16617414 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15797155 [patent_doc_number] => 20200121720 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-23 [patent_title] => NK-92 CELLS AND IL-15 AGONIST COMBINATION THERAPY [patent_app_type] => utility [patent_app_number] => 16/620791 [patent_app_country] => US [patent_app_date] => 2018-06-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6581 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16620791 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13476523 [patent_doc_number] => 20180289804 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-10-11 [patent_title] => ANTIBODY FORMULATION [patent_app_type] => utility [patent_app_number] => 16/007102 [patent_app_country] => US [patent_app_date] => 2018-06-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15919 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 113 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16007102 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17407185 [patent_doc_number] => 11248054 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-02-15 [patent_title] => Anti-IL1RAP antibodies and antibody drug conjugates [patent_app_type] => utility [patent_app_number] => 16/620386 [patent_app_country] => US [patent_app_date] => 2018-06-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 13 [patent_no_of_words] => 63567 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 165 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16620386 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13774763 [patent_doc_number] => 20190000920 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-03 [patent_title] => Methods of Treating Cancer [patent_app_type] => utility [patent_app_number] => 16/003590 [patent_app_country] => US [patent_app_date] => 2018-06-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36029 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16003590 [rel_patent_id] =>[rel_patent_doc_number] =>)